Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis
Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of trans...
Saved in:
Published in | Clinical pharmacokinetics Vol. 57; no. 4; pp. 491 - 503 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.04.2018
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 0312-5963 1179-1926 1179-1926 |
DOI | 10.1007/s40262-017-0568-7 |
Cover
Loading…
Abstract | Background
Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.
Objective
The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.
Methods
We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for
SLCO1B1
(encoding OATP1B1) and
ABCG2
(encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.
Results
Simulations based on the current hypothesis reasonably describe
SLCO1B1
and
ABCG2
genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.
Conclusion
This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics. |
---|---|
AbstractList | Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.Objective The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.Methods We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.Results Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.Conclusion This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics. Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates. Objective The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations. Methods We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects. Results Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. Conclusion This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics. Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates. The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations. We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects. Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics. Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.BACKGROUNDEthnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.OBJECTIVEThe objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.METHODSWe evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.RESULTSSimulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.CONCLUSIONThis hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics. |
Author | Barton, Hugh A. Li, Rui |
Author_xml | – sequence: 1 givenname: Rui orcidid: 0000-0003-1825-2401 surname: Li fullname: Li, Rui email: Rui.Li5@pfizer.com organization: Systems Modeling and Simulation, Medicine Design, World Wide Research and Development, Pfizer Inc – sequence: 2 givenname: Hugh A. surname: Barton fullname: Barton, Hugh A. organization: Translational Modeling and Simulation, Biomedicine Design, World Wide Research and Development, Pfizer Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28653144$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1uEzEUhUeoiKaFB2CDLLFhM2B7PD9mgTSNUorUqhEEttYdx8k4OHawPUDejYfD05QClWBlWT7fveden5PsyDqrsuwpwS8JxvWrwDCtaI5JneOyavL6QTYhpOY54bQ6yia4IDQveVUcZychbDDGDcX4UXZMm6osCGOT7Mfs-86Attqu0Sz2Vkv0CbyGThsd98it0MKDDTvno_Low9CF6CEqNO_Bb0G6z9qqqGVA2qILBSb2e9QGDRaBXaIpDBJuboncKBkD-qZjj1pjlFHo3Ksvg7JSqzB2um4Xc3JGbsiz6fv5a9SiKyV7sDqkHujKLZUZjbYWzD7o8Dh7uAIT1JPb8zT7eD5bTC_yy-u376btZS5ZjWPOKCeMpA3VDWcVpOUwSqFsmqrugHFJqqIs66ImlPGmY6A4rxhfqY4sy6JUuDjN3hzq7oZuq5ZS2bQEI3Zeb8HvhQMt_n6xuhdr91WUTfoWTlOBF7cFvEsThyi2OkhlDFjlhiBIMkgbzkmZpM_vSTdu8GngICjBnDaYUJJUz_50dGfl18cmATkIpHcheLW6kxAsxvCIQ3hECo8YwyPqxNT3GKkjRO3GobT5L0kPZEhd7Fr536b_Df0EPHnY2A |
CitedBy_id | crossref_primary_10_1007_s40262_020_00876_0 crossref_primary_10_1007_s11883_017_0701_y crossref_primary_10_1080_17425255_2021_1998455 crossref_primary_10_1016_j_ejps_2020_105280 crossref_primary_10_1002_jcph_1105 crossref_primary_10_1080_00498254_2019_1708514 crossref_primary_10_3390_ijms22062786 crossref_primary_10_1080_03602532_2024_2399523 crossref_primary_10_2174_1574884714666190408125206 crossref_primary_10_1007_s11095_021_03109_6 crossref_primary_10_1208_s12248_019_0337_7 crossref_primary_10_1007_s12272_023_01476_9 crossref_primary_10_1002_cpdd_1157 crossref_primary_10_1002_psp4_12582 crossref_primary_10_1002_cpdd_1044 crossref_primary_10_1124_dmd_118_083030 crossref_primary_10_1080_17425255_2020_1749595 crossref_primary_10_1124_dmd_118_084988 crossref_primary_10_3389_fphar_2021_698966 crossref_primary_10_1080_17425255_2023_2202813 crossref_primary_10_3390_ph17111411 crossref_primary_10_1002_prp2_890 |
Cites_doi | 10.1007/s00228-014-1800-0 10.1097/01.fpc.0000114750.08559.32 10.1038/clpt.2009.181 10.1124/pr.110.002857 10.1007/s11222-006-9438-0 10.2165/00003088-200342130-00005 10.1007/s10928-014-9357-1 10.1124/jpet.115.225045 10.1016/S0149-2918(03)80316-8 10.1158/1078-0432.CCR-04-0144 10.1097/00008571-200301000-00004 10.3389/fphar.2011.00041 10.1097/01.fpc.0000230422.50962.91 10.2165/11592480-000000000-00000 10.1038/sj.clpt.6100190 10.1124/dmd.104.001628 10.2133/dmpk.DMPK-12-RG-068 10.1016/S0009-9236(03)00060-2 10.1038/clpt.2012.221 10.1177/0091270002239702 10.1097/FPC.0b013e3282fb02a3 10.1002/jps.20502 10.1038/psp.2014.50 10.3109/00498254.2010.523736 10.1111/bcp.12377 10.2133/dmpk.DMPK-11-RV-099 10.1111/j.1365-2125.1990.tb03626.x 10.1007/s00228-006-0123-1 10.1124/dmd.115.063362 10.1016/j.clpt.2005.06.013 10.1097/FPC.0b013e3280ef698f 10.1016/j.clpt.2006.06.010 10.1007/s00228-014-1801-z 10.1111/j.1365-2710.2009.01127.x 10.1002/ijc.11669 10.1038/sj.clpt.6100267 10.1007/s10928-011-9232-2 10.1517/17425250902976854 10.1038/clpt.2009.79 10.1038/sj.clpt.6100220 |
ContentType | Journal Article |
Copyright | The Author(s) 2017 Copyright Springer Science & Business Media Apr 2018 |
Copyright_xml | – notice: The Author(s) 2017 – notice: Copyright Springer Science & Business Media Apr 2018 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 4T- 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1007/s40262-017-0568-7 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Docstoc Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1179-1926 |
EndPage | 503 |
ExternalDocumentID | PMC5856892 28653144 10_1007_s40262_017_0568_7 |
Genre | Journal Article |
GroupedDBID | --- -5G -BR -EM .GJ .XZ 0R~ 0VX 199 29B 2JY 34G 36B 39C 3V. 4.4 406 53G 5GY 5RE 6I2 6J9 6PF 7X7 88E 8FI 8FJ 8R4 8R5 8UJ 95. AAAUJ AABHQ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AANZL AARHV AASML AATNV AAWTL AAYQN AAYTO AAYZH ABAKF ABDZT ABFTV ABIPD ABJNI ABJOX ABKCH ABKMS ABKTR ABOCM ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFO ACGFS ACMJI ACMLO ACOKC ACPIV ACREN ACZOJ ADBBV ADFRT ADFZG ADHHG ADJJI ADQRH ADRFC ADURQ ADYOE ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AEYRQ AFALF AFBBN AFFNX AFKRA AFWTZ AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHIZS AHMBA AHSBF AIAKS AIGIU AILAN AIZAD AJRNO ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASPBG AVWKF AWSVR AXYYD AZFZN A~4 BENPR BGNMA BPHCQ BVXVI BYPQX C6C CAG CCPQU COF CS3 DCUDU DNIVK DPUIP DU5 EBLON EBS EJD EMOBN ESX F5P F8P FERAY FIGPU FLLZZ FNLPD FSGXE FYUFA HF~ HMCUK IAO IEA IHR IMOTQ INH INR ITC IWAJR J-C JZLTJ LGEZI LLZTM LOTEE M1P M4Y NADUK NQJWS NU0 NXXTH OAC OPC OVD P2P PQQKQ PROAC PSQYO Q2X ROL RSV RZALA SISQX SJYHP SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U5U U9L UAX UG4 UKHRP UNMZH UTJUX VDBLX VFIZW W48 WAF YQY Z0Y Z7U ZGI ZMTXR ZXP ~JE AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 4T- 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c470t-42914105678946a192422a58867ba49c1635573712498b4ae99649feb1d535e03 |
IEDL.DBID | C6C |
ISSN | 0312-5963 1179-1926 |
IngestDate | Thu Aug 21 14:13:09 EDT 2025 Tue Aug 05 10:38:24 EDT 2025 Fri Jul 25 05:04:28 EDT 2025 Thu Apr 03 06:58:33 EDT 2025 Thu Apr 24 22:55:02 EDT 2025 Tue Jul 01 01:31:33 EDT 2025 Fri Feb 21 02:27:38 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c470t-42914105678946a192422a58867ba49c1635573712498b4ae99649feb1d535e03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-1825-2401 |
OpenAccessLink | https://doi.org/10.1007/s40262-017-0568-7 |
PMID | 28653144 |
PQID | 2109280121 |
PQPubID | 32335 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5856892 proquest_miscellaneous_1914289915 proquest_journals_2109280121 pubmed_primary_28653144 crossref_primary_10_1007_s40262_017_0568_7 crossref_citationtrail_10_1007_s40262_017_0568_7 springer_journals_10_1007_s40262_017_0568_7 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-04-01 |
PublicationDateYYYYMMDD | 2018-04-01 |
PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: Switzerland – name: Auckland |
PublicationTitle | Clinical pharmacokinetics |
PublicationTitleAbbrev | Clin Pharmacokinet |
PublicationTitleAlternate | Clin Pharmacokinet |
PublicationYear | 2018 |
Publisher | Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
References | Niemi, Pasanen, Neuvonen (CR1) 2011; 63 Ieiri, Higuchi, Sugiyama (CR22) 2009; 5 Niemi (CR24) 2004; 14 Haario (CR15) 2006; 16 Kim, Joo, Park (CR31) 2010; 35 Keskitalo (CR7) 2009; 86 Singhvi (CR12) 1990; 29 Pasanen (CR38) 2006; 62 Martin (CR11) 2003; 25 Li (CR6) 2014; 41 Choi (CR43) 2008; 83 Sui (CR39) 2011; 46 Birmingham (CR30) 2015; 71 Wan (CR8) 2015; 354 Ieiri (CR18) 2007; 82 Lee (CR40) 2005; 78 Li, Barton, Maurer (CR20) 2014; 3 Mizuarai, Aozasa, Kotani (CR34) 2004; 109 Birmingham (CR13) 2015; 71 Deng (CR26) 2008; 18 Ho (CR23) 2007; 17 Warrington, Nagakawa, Hounslow (CR5) 2011; 31 Rodgers, Rowland (CR10) 2006; 95 Imai (CR36) 2002; 1 Peng (CR3) 2015; 43 Choi (CR25) 2011; 41 Oh (CR17) 2013; 28 Riedmaier (CR28) 2011; 2 Nakanishi, Tamai (CR32) 2012; 27 Kobayashi (CR37) 2005; 33 Riedmaier (CR29) 2010; 87 Pasanen (CR16) 2007; 82 Niemi (CR21) 2006; 16 Thomsen (CR4) 2003; 43 Zhu (CR41) 2013; 26 Tomita, Maeda, Sugiyama (CR2) 2013; 94 de Jong (CR33) 2004; 10 Prueksaritanont (CR19) 2014; 78 Shah, Betts (CR9) 2012; 39 Lennernas (CR14) 2003; 42 Zamber (CR35) 2003; 13 Niemi, Pasanen, Neuvonen (CR27) 2006; 80 Nishizato (CR42) 2003; 73 MK Pasanen (568_CR38) 2006; 62 KA Kim (568_CR31) 2010; 35 FA Jong de (568_CR33) 2004; 10 I Ieiri (568_CR22) 2009; 5 S Warrington (568_CR5) 2011; 31 JE Keskitalo (568_CR7) 2009; 86 H Haario (568_CR15) 2006; 16 T Prueksaritanont (568_CR19) 2014; 78 R Li (568_CR20) 2014; 3 D Kobayashi (568_CR37) 2005; 33 SM Sui (568_CR39) 2011; 46 PD Martin (568_CR11) 2003; 25 RH Ho (568_CR23) 2007; 17 JW Deng (568_CR26) 2008; 18 JH Choi (568_CR43) 2008; 83 T Nakanishi (568_CR32) 2012; 27 DK Shah (568_CR9) 2012; 39 Y Tomita (568_CR2) 2013; 94 SM Singhvi (568_CR12) 1990; 29 I Ieiri (568_CR18) 2007; 82 M Niemi (568_CR1) 2011; 63 MK Choi (568_CR25) 2011; 41 BK Birmingham (568_CR13) 2015; 71 Y Nishizato (568_CR42) 2003; 73 KW Peng (568_CR3) 2015; 43 H Lennernas (568_CR14) 2003; 42 MK Pasanen (568_CR16) 2007; 82 MS Thomsen (568_CR4) 2003; 43 Z Wan (568_CR8) 2015; 354 J Zhu (568_CR41) 2013; 26 M Niemi (568_CR27) 2006; 80 CP Zamber (568_CR35) 2003; 13 M Niemi (568_CR24) 2004; 14 ES Oh (568_CR17) 2013; 28 E Lee (568_CR40) 2005; 78 BK Birmingham (568_CR30) 2015; 71 R Li (568_CR6) 2014; 41 S Riedmaier (568_CR29) 2010; 87 Y Imai (568_CR36) 2002; 1 S Mizuarai (568_CR34) 2004; 109 T Rodgers (568_CR10) 2006; 95 M Niemi (568_CR21) 2006; 16 S Riedmaier (568_CR28) 2011; 2 |
References_xml | – volume: 71 start-page: 329 issue: 3 year: 2015 end-page: 340 ident: CR13 article-title: Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-014-1800-0 – volume: 14 start-page: 429 issue: 7 year: 2004 end-page: 440 ident: CR24 article-title: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) publication-title: Pharmacogenetics doi: 10.1097/01.fpc.0000114750.08559.32 – volume: 87 start-page: 65 issue: 1 year: 2010 end-page: 73 ident: CR29 article-title: UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2009.181 – volume: 63 start-page: 157 issue: 1 year: 2011 end-page: 181 ident: CR1 article-title: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake publication-title: Pharmacol Rev doi: 10.1124/pr.110.002857 – volume: 16 start-page: 339 issue: 4 year: 2006 end-page: 354 ident: CR15 article-title: DRAM: efficient adaptive MCMC publication-title: Stat Comput doi: 10.1007/s11222-006-9438-0 – volume: 42 start-page: 1141 issue: 13 year: 2003 end-page: 1160 ident: CR14 article-title: Clinical pharmacokinetics of atorvastatin publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342130-00005 – volume: 41 start-page: 197 issue: 3 year: 2014 end-page: 209 ident: CR6 article-title: A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-014-9357-1 – volume: 1 start-page: 611 issue: 8 year: 2002 end-page: 616 ident: CR36 article-title: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance publication-title: Mol Cancer Ther – volume: 354 start-page: 310 issue: 3 year: 2015 end-page: 315 ident: CR8 article-title: Marked alteration of rosuvastatin pharmacokinetics in healthy Chinese with ABCG2 34G>A and 421C>A homozygote or compound heterozygote publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.115.225045 – volume: 25 start-page: 2553 issue: 10 year: 2003 end-page: 2563 ident: CR11 article-title: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80316-8 – volume: 10 start-page: 5889 issue: 17 year: 2004 end-page: 5894 ident: CR33 article-title: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0144 – volume: 13 start-page: 19 issue: 1 year: 2003 end-page: 28 ident: CR35 article-title: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine publication-title: Pharmacogenetics doi: 10.1097/00008571-200301000-00004 – volume: 2 start-page: 41 year: 2011 ident: CR28 article-title: Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis publication-title: Front Pharmacol doi: 10.3389/fphar.2011.00041 – volume: 16 start-page: 801 issue: 11 year: 2006 end-page: 808 ident: CR21 article-title: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics publication-title: Pharmacogenet Genom doi: 10.1097/01.fpc.0000230422.50962.91 – volume: 31 start-page: 735 issue: 10 year: 2011 end-page: 743 ident: CR5 article-title: Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men publication-title: Clin Drug Investig doi: 10.2165/11592480-000000000-00000 – volume: 82 start-page: 541 issue: 5 year: 2007 end-page: 547 ident: CR18 article-title: SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100190 – volume: 33 start-page: 94 issue: 1 year: 2005 end-page: 101 ident: CR37 article-title: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta publication-title: Drug Metab Dispos doi: 10.1124/dmd.104.001628 – volume: 28 start-page: 196 issue: 3 year: 2013 end-page: 202 ident: CR17 article-title: Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-12-RG-068 – volume: 26 start-page: 577 issue: 3 year: 2013 end-page: 584 ident: CR41 article-title: Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males publication-title: Pak J Pharm Sci – volume: 73 start-page: 554 issue: 6 year: 2003 end-page: 565 ident: CR42 article-title: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(03)00060-2 – volume: 94 start-page: 37 issue: 1 year: 2013 end-page: 51 ident: CR2 article-title: Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.221 – volume: 43 start-page: 23 issue: 1 year: 2003 end-page: 28 ident: CR4 article-title: Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects publication-title: J Clin Pharmacol doi: 10.1177/0091270002239702 – volume: 18 start-page: 424 issue: 5 year: 2008 end-page: 433 ident: CR26 article-title: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 publication-title: Pharmacogenet Genom doi: 10.1097/FPC.0b013e3282fb02a3 – volume: 95 start-page: 1238 issue: 6 year: 2006 end-page: 1257 ident: CR10 article-title: Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions publication-title: J Pharm Sci doi: 10.1002/jps.20502 – volume: 3 start-page: e151 year: 2014 ident: CR20 article-title: Toward prospective prediction of pharmacokinetics in OATP1B1 genetic variant populations publication-title: CPT Pharmacomet Syst Pharmacol doi: 10.1038/psp.2014.50 – volume: 41 start-page: 24 issue: 1 year: 2011 end-page: 34 ident: CR25 article-title: Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors publication-title: Xenobiotica doi: 10.3109/00498254.2010.523736 – volume: 78 start-page: 587 issue: 3 year: 2014 end-page: 598 ident: CR19 article-title: Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12377 – volume: 27 start-page: 106 issue: 1 year: 2012 end-page: 121 ident: CR32 article-title: Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-11-RV-099 – volume: 29 start-page: 239 issue: 2 year: 1990 end-page: 243 ident: CR12 article-title: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1990.tb03626.x – volume: 62 start-page: 409 issue: 6 year: 2006 end-page: 415 ident: CR38 article-title: Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-006-0123-1 – volume: 43 start-page: 1045 issue: 7 year: 2015 end-page: 1055 ident: CR3 article-title: Ethnic variability in the expression of hepatic drug transporters: absolute quantification by an optimized targeted quantitative proteomic approach publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.063362 – volume: 78 start-page: 330 issue: 4 year: 2005 end-page: 341 ident: CR40 article-title: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.06.013 – volume: 17 start-page: 647 issue: 8 year: 2007 end-page: 656 ident: CR23 article-title: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3280ef698f – volume: 80 start-page: 356 issue: 4 year: 2006 end-page: 366 ident: CR27 article-title: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.06.010 – volume: 71 start-page: 341 issue: 3 year: 2015 end-page: 355 ident: CR30 article-title: Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-014-1801-z – volume: 35 start-page: 705 issue: 6 year: 2010 end-page: 712 ident: CR31 article-title: ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2009.01127.x – volume: 109 start-page: 238 issue: 2 year: 2004 end-page: 246 ident: CR34 article-title: Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 publication-title: Int J Cancer doi: 10.1002/ijc.11669 – volume: 83 start-page: 251 issue: 2 year: 2008 end-page: 257 ident: CR43 article-title: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100267 – volume: 39 start-page: 67 issue: 1 year: 2012 end-page: 86 ident: CR9 article-title: Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-011-9232-2 – volume: 5 start-page: 703 issue: 7 year: 2009 end-page: 729 ident: CR22 article-title: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425250902976854 – volume: 86 start-page: 197 issue: 2 year: 2009 end-page: 203 ident: CR7 article-title: ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2009.79 – volume: 82 start-page: 726 issue: 6 year: 2007 end-page: 733 ident: CR16 article-title: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100220 – volume: 46 start-page: 695 issue: 6 year: 2011 end-page: 700 ident: CR39 article-title: Effect of OATP1B1 521T>C heterogenesis on pharmacokinetic characteristics of rosuvastatin in Chinese volunteers publication-title: Acta Pharm Sin – volume: 71 start-page: 329 issue: 3 year: 2015 ident: 568_CR13 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-014-1800-0 – volume: 109 start-page: 238 issue: 2 year: 2004 ident: 568_CR34 publication-title: Int J Cancer doi: 10.1002/ijc.11669 – volume: 42 start-page: 1141 issue: 13 year: 2003 ident: 568_CR14 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342130-00005 – volume: 78 start-page: 330 issue: 4 year: 2005 ident: 568_CR40 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.06.013 – volume: 86 start-page: 197 issue: 2 year: 2009 ident: 568_CR7 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2009.79 – volume: 3 start-page: e151 year: 2014 ident: 568_CR20 publication-title: CPT Pharmacomet Syst Pharmacol doi: 10.1038/psp.2014.50 – volume: 87 start-page: 65 issue: 1 year: 2010 ident: 568_CR29 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2009.181 – volume: 43 start-page: 23 issue: 1 year: 2003 ident: 568_CR4 publication-title: J Clin Pharmacol doi: 10.1177/0091270002239702 – volume: 78 start-page: 587 issue: 3 year: 2014 ident: 568_CR19 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12377 – volume: 73 start-page: 554 issue: 6 year: 2003 ident: 568_CR42 publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(03)00060-2 – volume: 14 start-page: 429 issue: 7 year: 2004 ident: 568_CR24 publication-title: Pharmacogenetics doi: 10.1097/01.fpc.0000114750.08559.32 – volume: 94 start-page: 37 issue: 1 year: 2013 ident: 568_CR2 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.221 – volume: 43 start-page: 1045 issue: 7 year: 2015 ident: 568_CR3 publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.063362 – volume: 16 start-page: 339 issue: 4 year: 2006 ident: 568_CR15 publication-title: Stat Comput doi: 10.1007/s11222-006-9438-0 – volume: 28 start-page: 196 issue: 3 year: 2013 ident: 568_CR17 publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-12-RG-068 – volume: 17 start-page: 647 issue: 8 year: 2007 ident: 568_CR23 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3280ef698f – volume: 5 start-page: 703 issue: 7 year: 2009 ident: 568_CR22 publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425250902976854 – volume: 13 start-page: 19 issue: 1 year: 2003 ident: 568_CR35 publication-title: Pharmacogenetics doi: 10.1097/00008571-200301000-00004 – volume: 63 start-page: 157 issue: 1 year: 2011 ident: 568_CR1 publication-title: Pharmacol Rev doi: 10.1124/pr.110.002857 – volume: 95 start-page: 1238 issue: 6 year: 2006 ident: 568_CR10 publication-title: J Pharm Sci doi: 10.1002/jps.20502 – volume: 1 start-page: 611 issue: 8 year: 2002 ident: 568_CR36 publication-title: Mol Cancer Ther – volume: 26 start-page: 577 issue: 3 year: 2013 ident: 568_CR41 publication-title: Pak J Pharm Sci – volume: 354 start-page: 310 issue: 3 year: 2015 ident: 568_CR8 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.115.225045 – volume: 35 start-page: 705 issue: 6 year: 2010 ident: 568_CR31 publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2009.01127.x – volume: 31 start-page: 735 issue: 10 year: 2011 ident: 568_CR5 publication-title: Clin Drug Investig doi: 10.2165/11592480-000000000-00000 – volume: 29 start-page: 239 issue: 2 year: 1990 ident: 568_CR12 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1990.tb03626.x – volume: 25 start-page: 2553 issue: 10 year: 2003 ident: 568_CR11 publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80316-8 – volume: 46 start-page: 695 issue: 6 year: 2011 ident: 568_CR39 publication-title: Acta Pharm Sin – volume: 33 start-page: 94 issue: 1 year: 2005 ident: 568_CR37 publication-title: Drug Metab Dispos doi: 10.1124/dmd.104.001628 – volume: 41 start-page: 197 issue: 3 year: 2014 ident: 568_CR6 publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-014-9357-1 – volume: 80 start-page: 356 issue: 4 year: 2006 ident: 568_CR27 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.06.010 – volume: 83 start-page: 251 issue: 2 year: 2008 ident: 568_CR43 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100267 – volume: 71 start-page: 341 issue: 3 year: 2015 ident: 568_CR30 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-014-1801-z – volume: 27 start-page: 106 issue: 1 year: 2012 ident: 568_CR32 publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-11-RV-099 – volume: 82 start-page: 541 issue: 5 year: 2007 ident: 568_CR18 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100190 – volume: 2 start-page: 41 year: 2011 ident: 568_CR28 publication-title: Front Pharmacol doi: 10.3389/fphar.2011.00041 – volume: 10 start-page: 5889 issue: 17 year: 2004 ident: 568_CR33 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0144 – volume: 41 start-page: 24 issue: 1 year: 2011 ident: 568_CR25 publication-title: Xenobiotica doi: 10.3109/00498254.2010.523736 – volume: 16 start-page: 801 issue: 11 year: 2006 ident: 568_CR21 publication-title: Pharmacogenet Genom doi: 10.1097/01.fpc.0000230422.50962.91 – volume: 62 start-page: 409 issue: 6 year: 2006 ident: 568_CR38 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-006-0123-1 – volume: 39 start-page: 67 issue: 1 year: 2012 ident: 568_CR9 publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-011-9232-2 – volume: 82 start-page: 726 issue: 6 year: 2007 ident: 568_CR16 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100220 – volume: 18 start-page: 424 issue: 5 year: 2008 ident: 568_CR26 publication-title: Pharmacogenet Genom doi: 10.1097/FPC.0b013e3282fb02a3 |
SSID | ssj0008200 |
Score | 2.3667002 |
Snippet | Background
Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is... Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A... Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is... |
SourceID | pubmedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 491 |
SubjectTerms | Asian Continental Ancestry Group - genetics Atorvastatin - administration & dosage Atorvastatin - pharmacokinetics ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism Breast cancer Carbamates - administration & dosage Carbamates - pharmacokinetics Computer Simulation Cultural differences Drug dosages European Continental Ancestry Group - genetics Gene Frequency Genes Genotype Haplotypes Healthy Volunteers Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacokinetics Hypotheses Internal Medicine Liver-Specific Organic Anion Transporter 1 - genetics Liver-Specific Organic Anion Transporter 1 - metabolism Medicine Medicine & Public Health Metabolism Minority & ethnic groups Models, Biological Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Original Original Research Article Pharmacogenomic Variants Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Phenotype Piperidines - administration & dosage Piperidines - pharmacokinetics Polypeptides Population genetics Pravastatin - administration & dosage Pravastatin - pharmacokinetics Proteins Quinolines - administration & dosage Quinolines - pharmacokinetics Rosuvastatin Calcium - administration & dosage Rosuvastatin Calcium - pharmacokinetics Studies |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEB5a59JL6btq0jKFkkMbUb131UuRjU0oJBXBKbkJaSURUyOntnPwf8uP68yuHrihOQppJS0zOzPf7sw3AJ-UCIuKK3M9oSI7iEppS4oDbCWLXNal5we6TefZeXR6Gfy4Cq_aDbdNm1bZ2URtqMuV4j3yrwRNYo_Nqfv95o_NXaP4dLVtofEYDsgEy3AEB-PpeXrR22Lyb44p1SHIRbrWnWty8Rwhp4jTEoRNQYC0xb5nuhdu3s-a_OfoVHuk2TN42oaSmBjZP4dHVfMCjlPDRb07wflQWrU5wWNMB5bq3Uu44-w70x4Cp9vrZqHwF-FmQ9u9w1WNA-_5Gtm-aB7b_i2_KTzlN-OiQVPLtMOEKzIxb0qc5NxMja9oJG_1bJB3fDFZLsnP4WxtMrgJpvOXfibz1B27euR4cpF-wwTPKq5J1jTSyA3buGweOwqVV3A5m84np3bbysFWgXC2Nnk9nVBKrjEOopxRn-floZSRKPIgVi7HPcIX3ApbFkFeEQwL4pocSRn6YeX4r2HUrJrqLaCjShF7KioKRdGUJrNxo7II6oqgn6prC5xOjJlqec653cYy6xmateQzknzGks-EBZ_7ITeG5OOhh4863cja9b7JBu204GN_m1YqH7_kTbW63WTMpMfw1g0teGNUqf8a1wf7hG0tEHtK1j_ALOD7d5rFtWYDJ7wXydiz4EunjsNv_XcS7x6exCE8ocBQmgylIxht17fVewq-tsWHdoX9BbFsLFM priority: 102 providerName: ProQuest |
Title | Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis |
URI | https://link.springer.com/article/10.1007/s40262-017-0568-7 https://www.ncbi.nlm.nih.gov/pubmed/28653144 https://www.proquest.com/docview/2109280121 https://www.proquest.com/docview/1914289915 https://pubmed.ncbi.nlm.nih.gov/PMC5856892 |
Volume | 57 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9tAEB6aBEovpU0fUZuaKZQc2ojquSv1JhmbULBrglN8E9JKIqZGLpZz8H_rj-uMVpJx0hZ6Mkb7sNGsZj7NfN8AfFDSzwpm5jpSCdMTeWAGFAeYKsjSoMwd12vadE6m4urG-7rwF61YNHNh7uXvP9eEbwQXD0iTXHVgyiM48VlmjPOyYtg_dMmRWZqTQ9iKjKpLYP5piUMX9CCufFgeeS9H2rie8TN42saMGOmb_BweFdUpPJ60WfFTuJhp_endJc73dKr6Ei9wtlem3r2AX1xxp1tC4Gh7Wy0VfiesrKW6d7guca91vkF-pjTatf0qP2g7XhmXFWr-0g4jZmFiWuU4TLmBGn-jmfx6p0Z-y4vRakW-DccbXbVN0Jx3-hbNZ3ZsNzPj4fXsC0Y4KZiH3EhHIzdpY6o8drIpL-FmPJoPr8y2fYOpPGltTfJ0TREpucPQEykjPcdJ_SAQMku9UNkc60hXcvvrIPPSgqCXF5bkPHLf9QvLfQXH1boqzgAtlcvQUSLLFEVQjYCNLfLMKwuCe6osDbC6O5qoVtucW2yskl6VuTGChIwgYSNIpAEf-yk_tbDHvwafd2aStGe8Tggshw47eNuA9_1lOp2cckmrYn1XJ6yex5DW9g14ra2q3405wS7hWQPkgb31A1j5-_BKtbxtFMAJ44kgdAz41Fnm_mf99U-8-a_Rb-EJxYaBLlI6h-Pt5q54R_HXNhvAkVzIAZxE4zie0mc8ms6uB815_A0sGCq3 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEB6V9gAXxD-GAoMEPUAtYsf22kgIOSFRSpsQVWnVm7HXazUickqcCuWleAIejhlvbCtU9NZjZO9urJmdmW935huAN1K4ieLKXFtIz3S81Dd9igNM6Sexn6V22ynbdA5H3uDE-Xrmnm3B76oWhtMqK5tYGup0LvmM_ANBk8Bmc2p9vvhpctcovl2tWmhotThUq18E2YpPB19Ivm9tu9-bdAfmuquAKR3RWppkgMvcRrLSgePFDEBsO3Z93xNJ7ATSYhcs2oK7MvuJEytCBE6QkU1L3barWm2a9xbsUJgR0C7a6fRG4-Pa9pM_benSIIJ4pNvVPSoX6xFS8zgNQpi0uG-KTU94Jby9mqX5z1Vt6QH79-DuOnTFUOvafdhS-QPYG2vu69U-TppSrmIf93DcsGKvHsIfzvbT7SiwtzzPpxJPCadrmvAVzjNseNYXyPas5M2tZ_lB4TDPjNMcde3UCkOuAMU4T7Ebc_M2_kUj-WipQD5hxnA2I7-K_YXOGJ-qglf6Fk7GVscqR3a6x-OPGOJQcQ10SVuN3CCOy_Sxomx5BCc3IuTHsJ3Pc_UUsCVTEdjSSxJJ0VtJnmN5aeJkiqCmzDIDWpUYI7nmVef2HrOoZoQuJR-R5COWfCQMeFcPudCkIte9vFvpRrS2L0XU7AYDXtePyTLwdU-cq_llETFzH8NpyzXgiValejWuR24TljZAbChZ_QKzjm8-yafnJfs44UvPD2wD3lfq2Pyt_37Es-s_4hXcHkyGR9HRwejwOdyhoNTX2VG7sL1cXKoXFPgtk5fr3Ybw_aY3-F-EKmUa |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9NADLdGJyFeEN9kDDAS7AEWrUmT3AUJobZrtTFWoqlDewvJ5aJVq9LRdEL91xB_HHa-qjKxtz1Wyd01ss_2787-GeCtEm6suTLXFsozHS-RpqQ4wFQyjmSa2B2naNN5PPIOTp0vZ-7ZBvyua2E4rbK2iYWhTmaKz8j3CJr4NptTay-t0iKC_eHny58md5Dim9a6nUapIkd6-YvgW_7pcJ9k_c62h4Nx_8CsOgyYyhHthUnGuMhzJIvtO17EYMS2I1dKT8SR4yuL3bHoCO7QLGMn0oQOHD8l-5a4HVe3OzTvHdgU5BVlCzZ7g1Fw0vgB8q3tskyI4B7peX2nyoV7hNo8TokQJi0uTbHuFa-FutczNv-5ti284fAB3K_CWOyWevcQNnT2CHaCkgd7uYvjVVlXvos7GKwYspeP4Q9n_pWtKXCwOM8mCr8TZi8pw5c4S3HFuT5Htm0Fh24zywWFxjwzTjIs66iW2OVqUIyyBPsRN3LjXzSSj5ly5NNm7E6n5GNxOC-zxyc655W-dceB1bOKkb3-SfARu3isuR66oLBGbhbHJftY07c8gdNbEfJTaGWzTD8HbKtE-Lby4lhRJFcQ6VheEjupJtip0tSAdi3GUFUc69zqYxo27NCF5EOSfMiSD4UB75shlyXByE0vb9e6EVa2Jg9XO8OAN81jshJ89RNlenaVh8zix9Dacg14VqpSsxrXJncIVxsg1pSseYEZyNefZJPzgomcsKYnfduAD7U6rv7Wfz9i6-aPeA13aWOHXw9HRy_gHsWnskyU2obWYn6lX1IMuIhfVZsN4cdt7--_W1lpRg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Explaining+Ethnic+Variability+of+Transporter+Substrate+Pharmacokinetics+in+Healthy+Asian+and+Caucasian+Subjects+with+Allele+Frequencies+of+OATP1B1+and+BCRP%3A+A+Mechanistic+Modeling+Analysis&rft.jtitle=Clinical+pharmacokinetics&rft.au=Li%2C+Rui&rft.au=Barton%2C+Hugh+A.&rft.date=2018-04-01&rft.pub=Springer+International+Publishing&rft.issn=0312-5963&rft.eissn=1179-1926&rft.volume=57&rft.issue=4&rft.spage=491&rft.epage=503&rft_id=info:doi/10.1007%2Fs40262-017-0568-7&rft.externalDocID=10_1007_s40262_017_0568_7 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0312-5963&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0312-5963&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0312-5963&client=summon |